BioPharmSignal logoBioPharmSignal

Biotech News

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology (KURA)Kura Oncology2026-06-25 13:46 ESTClinical readout

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS

Open original release

Related news

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports First Quarter 2026 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

KURAKura Oncology2026-06-25 13:46 EST

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

View all latest news

Kura Oncology

Kura Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.

Recent company news

KURAKura Oncology2026-06-26 08:46 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KURAKura Oncology2026-06-26 08:46 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-26 08:46 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-06-26 08:46 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-06-26 08:46 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States